-transparent.png){kind=logo}
Synthetic rat-human corticotropin releasing-factor (CRF), in doses between 10(-12) M and 10(-8) M, significantly stimulates the release of immunoreactive beta-endorphin and dynorphin-A from rat hypothalamic slices superfused in vitro. With prolonged exposure to CRF, there is a reduction in the release of both opioids which can be reversed by the addition of naloxone. The latter result indicates the involvement of autoregulatory mechanisms in the control of opioid neuronal function.
Related Publications
O F Almeida, and
K E Nikolarakis, and
A Herz
January 1986,
Peptides,
O F Almeida, and
K E Nikolarakis, and
A Herz
January 1992,
Peptides,
O F Almeida, and
K E Nikolarakis, and
A Herz
September 1968,
Nihon Ishikai zasshi. Journal of the Japan Medical Association,
O F Almeida, and
K E Nikolarakis, and
A Herz
May 1987,
No shinkei geka. Neurological surgery,
O F Almeida, and
K E Nikolarakis, and
A Herz
July 1966,
Horumon to rinsho. Clinical endocrinology,
O F Almeida, and
K E Nikolarakis, and
A Herz
May 1969,
Nihon rinsho. Japanese journal of clinical medicine,
O F Almeida, and
K E Nikolarakis, and
A Herz
February 1989,
Proceedings of the National Academy of Sciences of the United States of America,
O F Almeida, and
K E Nikolarakis, and
A Herz
January 1993,
Ciba Foundation symposium,
O F Almeida, and
K E Nikolarakis, and
A Herz
March 1992,
Endocrinology,
O F Almeida, and
K E Nikolarakis, and
A Herz
December 1970,
Nihon Naibunpi Gakkai zasshi,
